ABCL
Price
$4.18
Change
-$0.12 (-2.79%)
Updated
Aug 29 closing price
Capitalization
1.25B
73 days until earnings call
CYBN
Price
$7.48
Change
-$0.16 (-2.09%)
Updated
Aug 29 closing price
Capitalization
179.79M
Interact to see
Advertisement

ABCL vs CYBN

Header iconABCL vs CYBN Comparison
Open Charts ABCL vs CYBNBanner chart's image
AbCellera Biologics
Price$4.18
Change-$0.12 (-2.79%)
Volume$3.62M
Capitalization1.25B
Cybin
Price$7.48
Change-$0.16 (-2.09%)
Volume$368.4K
Capitalization179.79M
ABCL vs CYBN Comparison Chart in %
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. CYBN commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and CYBN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (ABCL: $4.18 vs. CYBN: $7.48)
Brand notoriety: ABCL and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 61% vs. CYBN: 87%
Market capitalization -- ABCL: $1.25B vs. CYBN: $179.79M
ABCL [@Biotechnology] is valued at $1.25B. CYBN’s [@Biotechnology] market capitalization is $179.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, ABCL is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while CYBN’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 5 bearish.
  • CYBN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -4.78% price change this week, while CYBN (@Biotechnology) price change was +4.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.25B) has a higher market cap than CYBN($180M). ABCL YTD gains are higher at: 42.662 vs. CYBN (-15.193). CYBN has higher annual earnings (EBITDA): -152.51M vs. ABCL (-197.92M). ABCL has more cash in the bank: 553M vs. CYBN (119M). CYBN has less debt than ABCL: CYBN (44.5M) vs ABCL (142M). ABCL has higher revenues than CYBN: ABCL (32.9M) vs CYBN (0).
ABCLCYBNABCL / CYBN
Capitalization1.25B180M694%
EBITDA-197.92M-152.51M130%
Gain YTD42.662-15.193-281%
P/E RatioN/AN/A-
Revenue32.9M0-
Total Cash553M119M465%
Total Debt142M44.5M319%
FUNDAMENTALS RATINGS
CYBN: Fundamental Ratings
CYBN
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLCYBN
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JEMCX34.50N/A
N/A
JPMorgan Emerging Markets Equity C
FAFDX39.13N/A
N/A
Fidelity Advisor Financials A
WBBIX10.55N/A
N/A
TETON Westwood Balanced I
GRSRX55.47N/A
N/A
Cohen & Steers Global Realty R
NWZMX21.86N/A
N/A
Nationwide Loomis All Cap Gr R6

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-2.09%
ATAI - CYBN
42%
Loosely correlated
-1.51%
RXRX - CYBN
35%
Loosely correlated
-3.39%
ABSI - CYBN
35%
Loosely correlated
-3.24%
EYPT - CYBN
30%
Poorly correlated
-0.26%
SPRC - CYBN
29%
Poorly correlated
-18.81%
More